Details for Patent: 12,728,116

« Back to Dashboard

Which drugs does patent 12,728,116 protect, and when does it expire?

Patent 12,728,116 protects PONVORY and is included in one NDA.

This patent has three patent family members in three countries.

Drugs Protected by US Patent 12,728,116

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes						TREATMENT OF RELAPSING FORMS OF EARLY-STAGE MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No						TREATMENT OF RELAPSING FORMS OF EARLY-STAGE MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS

International Family Members for US Patent 12,728,116

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3220723
European Patent Office	4415712
World Intellectual Property Organization (WIPO)	2023061939